Viridian Therapeutics (VRDN) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Viridian Therapeutics (NASDAQ: VRDN) recently:

• 9/13/2024 – Viridian Therapeutics had its price target raised by analysts at Royal Bank of Canada from $35.00 to $44.00. They now have an “outperform” rating on the stock.
• 9/12/2024 – Viridian Therapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $31.00. They now have a “buy” rating on the stock.
• 9/11/2024 – Viridian Therapeutics had its price target raised by analysts at Needham & Company LLC from $30.00 to $38.00. They now have a “buy” rating on the stock.
• 9/10/2024 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
• 9/10/2024 – Viridian Therapeutics had its price target raised by analysts at BTIG Research from $46.00 to $56.00. They now have a “buy” rating on the stock.
• 8/30/2024 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
• 8/28/2024 – Viridian Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
• 8/15/2024 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
• 8/12/2024 – Viridian Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $28.00 price target on the stock, down previously from $31.00.
• 7/29/2024 – Viridian Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.

Viridian Therapeutics Trading Down 2.2 %

Shares of NASDAQ:VRDN traded down $0.48 during midday trading on Monday, reaching $21.58. The company’s stock had a trading volume of 1,467,389 shares, compared to its average volume of 1,115,420. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -4.80 and a beta of 1.03. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics, Inc. has a 1 year low of $10.93 and a 1 year high of $24.18. The business has a 50 day moving average price of $15.39 and a 200 day moving average price of $14.98.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. Research analysts forecast that Viridian Therapeutics, Inc. will post -3.93 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC lifted its stake in shares of Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after buying an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC boosted its stake in Viridian Therapeutics by 108.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after acquiring an additional 6,500 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after acquiring an additional 1,688 shares in the last quarter.

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.